keyword
MENU ▼
Read by QxMD icon Read
search

Adenocarcinoma pancreatic

keyword
https://www.readbyqxmd.com/read/29224225/down-regulation-of-15-pgdh-by-interleukin-1-beta-from-activated-macrophages-leads-to-poor-prognosis-in-pancreatic-cancer
#1
Kota Arima, Yoshihiro Komohara, Luke Bu, Masayo Tsukamoto, Rumi Itoyama, Keisuke Miyake, Tomoyuki Uchihara, Yoko Ogata, Shigeki Nakagawa, Hirohisa Okabe, Katsunori Imai, Daisuke Hashimoto, Akira Chikamoto, Yo-Ichi Yamashita, Hideo Baba, Takatsugu Ishimoto
Chronic inflammation has a crucial role in cancer development and the progression of various tumors, including pancreatic ductal adenocarcinoma (PDAC). The arachidonate cascade is a major inflammatory pathway that produces several metabolites, such as prostaglandin E2 (PGE2 ). The enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) degrades prostaglandin and is frequently decreased in several types of cancer; however, the molecular mechanisms of 15-PGDH suppression are unclear. The current study was conducted to elucidate the molecular mechanisms and clinical significance of 15-PGDH suppression in PDAC...
December 10, 2017: Cancer Science
https://www.readbyqxmd.com/read/29223478/phase-ii-trial-of-veliparib-in-patients-with-previously-treated-brca-mutated-pancreas-ductal-adenocarcinoma
#2
Maeve A Lowery, David P Kelsen, Marinela Capanu, Sloane C Smith, Jonathan W Lee, Zsofia K Stadler, Malcolm J Moore, Hedy L Kindler, Talia Golan, Amiel Segal, Hannah Maynard, Ellen Hollywood, MaryEllen Moynahan, Erin E Salo-Mullen, Richard Kinh Gian Do, Alice P Chen, Kenneth H Yu, Laura H Tang, Eileen M O'Reilly
PURPOSE: BRCA-associated cancers have increased sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPis). This single arm, non-randomised, multicentre phase II trial evaluated the response rate of veliparib in patients with previously treated BRCA1/2- or PALB2-mutant pancreatic adenocarcinoma (PDAC). METHODS: Patients with stage III/IV PDAC and known germline BRCA1/2 or PALB2 mutation, 1-2 lines of treatment, Eastern Cooperative Oncology Group 0-2, were enrolled...
December 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29223362/autophagy-inhibition-in-pancreatic-adenocarcinoma
#3
REVIEW
Brian A Boone, Herbert J Zeh, Nathan Bahary
Although some progress has been made in recent years with the development of more effective chemotherapy regimens, new treatment approaches are needed to improve outcomes for patients with pancreatic adenocarcinoma. The cellular process of autophagy, a cell survival mechanism that allows cancer cells to survive the hazardous conditions of the tumor microenvironment and treatment, has emerged as a viable target in pancreatic cancer. We review the mechanism of autophagy, its role in pancreatic carcinogenesis, the preclinical and clinical evidence supporting targeting autophagy in patients with pancreatic adenocarcinoma, and areas of future investigation that hold promise for improving this treatment approach...
October 28, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29222037/diabetes-as-risk-factor-for-pancreatic-cancer-hyperglycemia-promotes-epithelial-mesenchymal-transition-and-stem-cell-properties-in-pancreatic-ductal-epithelial-cells
#4
Sascha Rahn, Vivien Zimmermann, Fabrice Viol, Hendrike Knaack, Kerstin Stemmer, Lena Peters, Lennart Lenk, Hendrik Ungefroren, Dieter Saur, Heiner Schäfer, Ole Helm, Susanne Sebens
Type 2 diabetes mellitus (T2DM) is associated with hyperglycemia and a risk to develop pancreatic ductal adenocarcinoma (PDAC), one of the most fatal malignancies. Cancer stem cells (CSC) are essential for initiation and maintenance of tumors, and acquisition of CSC-features is linked to epithelial-mesenchymal-transition (EMT). The present study investigated whether hyperglycemia promotes EMT and CSC-features in premalignant and malignant pancreatic ductal epithelial cells (PDEC). Under normoglycemia (5 mM d-glucose), Panc1 PDAC cells but not premalignant H6c7-kras cells exhibited a mesenchymal phenotype along with pronounced colony formation...
December 5, 2017: Cancer Letters
https://www.readbyqxmd.com/read/29221990/molecular-and-cellular-mechanisms-of-chemoresistance-in-pancreatic-cancer
#5
REVIEW
Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco Falasca
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, embolization, radiation, chemotherapy, immunotherapy and use of other more targeted drugs. In this review, we describe the cellular and molecular effects of current chemotherapy drugs such as gemcitabine, FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and ABRAXANE (nab-Paclitaxel), which have shown a survival benefit, although modest, for pancreatic cancer patients...
November 22, 2017: Advances in Biological Regulation
https://www.readbyqxmd.com/read/29221926/plasma-protein-profiling-of-patients-with-intraductal-papillary-mucinous-neoplasm-of-the-pancreas-as-potential-precursor-lesions-of-pancreatic-cancer
#6
Maria Ilies, Praveen Kumar Sappa, Cristina Adela Iuga, Felicia Loghin, Manuela Gesell Salazar, Frank Ulrich Weiss, Georg Beyer, Markus M Lerch, Uwe Völker, Julia Mayerle, Elke Hammer
Efforts for the early diagnosis of the pancreatic ductal adenocarcinoma (PDAC) have recently been driven to one of the precursor lesions, namely intraductal papillary mucinous neoplasm of the pancreas (IPMN). Only a few studies have focused on IPMN molecular biology and its overall progression to cancer. Therefore, IPMN lacks comprehensive characterization which makes its clinical management controversial. In this study, we characterized plasma proteins in the presence of IPMNs in comparison to healthy controls, chronic pancreatitis, and PDAC by a proteomics approach using data-independent acquisition based mass spectrometry...
December 5, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29221879/surveillance-of-patients-with-intraductal-papillary-mucinous-neoplasm-with-and-without-pancreatectomy-with-special-reference-to-the-incidence-of-concomitant-pancreatic-ductal-adenocarcinoma
#7
Kenjiro Date, Takao Ohtsuka, So Nakamura, Naoki Mochidome, Yasuhisa Mori, Yoshihiro Miyasaka, Yoshinao Oda, Masafumi Nakamura
BACKGROUND: The presence of an intraductal papillary mucinous neoplasm (IPMN) is important in the detection of concomitant pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to elucidate the incidence and timing of development of concomitant PDAC in patients with and without pancreatectomy for IPMN. METHODS: We reviewed retrospectively the surveillance data for 22 patients who underwent pancreatectomy for PDAC concomitant with IPMN (PDAC-resection group), 180 who underwent pancreatectomy for IPMN (IPMN-resection group), and 263 whose IPMNs were left untreated (non-resection group)...
December 5, 2017: Surgery
https://www.readbyqxmd.com/read/29221789/pretherapy-neutrophil-to-lymphocyte-ratio-and-platelet-to-lymphocyte-ratio-do-not-predict-survival-in-resectable-pancreatic-cancer
#8
Akhil Chawla, Tiffany L Huang, Andrew M Ibrahim, Jeffrey M Hardacre, Christopher Siegel, John B Ammori
BACKGROUND: Pretherapy serum neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have both been identified as prognostic in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to identify the prognostic implication of pretherapy NLR and PLR in patients with resectable PDAC. METHODS: Data were collected retrospectively on patients operated at our institution between 2004 and 2014. A Cox proportional hazards model was used to investigate the relationship between clinical and pathological parameters, NLR and PLR to overall survival (OS)...
December 5, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/29221719/integration-of-different-criteria-for-borderline-resectable-pancreatic-cancer-using-classification-tree-analysis-the-use-of-radiological-tumour-vascular-interface-in-correlation-with-surgical-and-pathological-outcomes
#9
J A Hwang, K M Jang, S H Kim, T W Kang, K D Song, D I Cha, S Ahn
AIM: To integrate various criteria for borderline resectable pancreatic cancer (BRPC) based on radiological parameters using classification tree analysis. MATERIALS AND METHODS: The institutional review board approved this retrospective study and waived the requirement for informed consent. Two hundred and thirty-five tumour-vein interfaces and 67 tumour-artery interfaces in 245 patients with surgically confirmed pancreatic ductal adenocarcinoma who underwent both preoperative computed tomography (CT) and magnetic resonance imaging (MRI) were assessed by two independent readers...
December 5, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/29221632/transarterial-chemoembolization-in-pancreatic-adenocarcinoma-with-liver-metastases-mr-based-tumor-response-evaluation-apparent-diffusion-coefficient-adc-patterns-and-survival-rates
#10
Thomas J Vogl, Sherif A Mohamed, Moritz H Albrecht, Tatjana Gruber-Roh, Han Lin, Nour Eldin A Nour Eldin, Iliana Bednarova, Nagy N Naguib, Bita Panahi
PURPOSE: To retrospectively investigate the effectiveness of triple drug combination transarterial chemoembolization (TACE) on local tumor response and survival in patients with liver metastases from pancreatic cancer. Also, this study will evaluate the variances in response regarding the number of metastases, assess the correlation between tumor response and the changes in the apparent diffusion coefficients (ADC) in diffusion weighted (DW) MRI. MATERIALS AND METHODS: One hundred and twelve patients (58 men and 54 women; mean age 57) with malignant liver metastases from pancreatic adenocarcinoma underwent at least one session of TACE with a chemotherapeutic combination of mitomycin C, cisplatin, and gemcitabine...
December 5, 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/29221165/angiogenesis-in-adenosquamous-cancer-of-pancreas
#11
Nicola Silvestris, Katia Danza, Vito Longo, Oronzo Brunetti, Livia Fucci, Antonella Argentiero, Angela Calabrese, Ivana Cataldo, Roberto Tamma, Domenico Ribatti, Stefania Tommasi
Adenosquamous carcinoma of the pancreas (ASCP) is an uncommon variant of exocrine pancreatic malignancies, characterized by a histological admixture of adenomatous and squamous cell elements. This cancer is characterized by a poorly differentiated histology and a poorer clinical outcome compared to pancreatic ductal adenocarcinoma (PDAC). Unlike PDAC, that is characterized by a low microvascular density (MVD) and collapsed vasculature, no data are available about angiogenesis in ASPC. Immunohistochemical evaluation of MVD and trypatse-positive mast cells (MCs) were performed on a single case of ASCP compared to PDAC...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29221133/endogenous-glutamine-decrease-is-associated-with-pancreatic-cancer-progression
#12
Cecilia Roux, Chiara Riganti, Sammy Ferri Borgogno, Roberta Curto, Claudia Curcio, Valeria Catanzaro, Giuseppe Digilio, Sergio Padovan, Maria Paola Puccinelli, Monica Isabello, Silvio Aime, Paola Cappello, Francesco Novelli
Pancreatic ductal adenocarcinoma (PDAC) is becoming the second leading cause of cancer-related death in the Western world. The mortality is very high, which emphasizes the need to identify biomarkers for early detection. As glutamine metabolism alteration is a feature of PDAC, its in vivo evaluation may provide a useful tool for biomarker identification. Our aim was to identify a handy method to evaluate blood glutamine consumption in mouse models of PDAC. We quantified the in vitro glutamine uptake by Mass Spectrometry (MS) in tumor cell supernatants and showed that it was higher in PDAC compared to non-PDAC tumor and pancreatic control human cells...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29218259/melena-as-initial-presentation-of-adenocarcinoma-in-pancreatic-tail
#13
Stella Pak, Damian Valencia, James Kim, Christine Dee
Melena associated with gastric varices, in the setting of possible obstructing pancreatic adenocarcinoma, has been poorly documented as an initial presenting sign for pancreatic malignancy. Considering the late presentation of patients with pancreatic malignancy, it is important to consider all potential presenting symptoms for the early detection and treatment of pancreatic malignancy. Below, we present a patient with no history of liver pathology, who presents with melena and gastric varices, likely relating to portal hypertension in the setting of an obstructing pancreatic malignancy...
October 4, 2017: Curēus
https://www.readbyqxmd.com/read/29217901/xanthogranulomatous-cholecystitis-analysis-of-108-patients
#14
Osman Yucel, Mehmet Ali Uzun, Metin Tilki, Sevcan Alkan, Zeynep Gamze Kilicoglu, Ceren Canbey Goret
The aim of this study was to evaluate the clinical and radiological features of xanthogranulomatous cholecystitis (XGC) and the results of surgical treatment. This retrospective study concerns clinical, radiological, and surgical data as well as histopathological findings and postoperative results of 108 patients with XGC who were identified after evaluating 7916 cholecystectomy specimens between 2004 and 2014 in a single institute. One hundred eight patients with XGC were evaluated (56 males and 52 females, mean age 62...
December 2017: Indian Journal of Surgery
https://www.readbyqxmd.com/read/29217216/corrigendum-to-expression-of-polymeric-immunoglobulin-receptor-and-stromal-activity-in-pancreatic-ductal-adenocarcinoma-pancreatology-17-2017-295-302
#15
Prabhu Arumugam, Satyajit Bhattacharya, Joanne Chin-Aleong, Melania Capaso, M Kocher Hemant
No abstract text is available yet for this article.
December 4, 2017: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/29216749/impact-of-palliative-chemotherapy-and-travel-distance-on-hospice-referral-in-patients-with-stage-iv-pancreatic-cancer-a-retrospective-analysis-within-a-veterans-administration-medical-center
#16
Jennifer M Duff, Ryan M Thomas
BACKGROUND: Metastatic pancreatic ductal adenocarcinoma (mPDAC) has a poor prognosis despite chemotherapy advancements. Although hospice utilization has increased, timing of referral is not always optimal. AIM: To investigate whether palliative chemotherapy and travel distance to the treatment center impact hospice referral patterns in veterans of the US military in order to identify potential areas for improving referral timing. DESIGN: Demographic and clinical data were collected retrospectively according to the timing of hospice referral...
January 1, 2017: American Journal of Hospice & Palliative Care
https://www.readbyqxmd.com/read/29216274/functional-analysis-of-a-cdkn2a-5-utr-germline-variant-associated-with-pancreatic-cancer-development
#17
William Bruno, Virginia Andreotti, Alessandra Bisio, Lorenza Pastorino, Giuseppe Fornarini, Stefania Sciallero, Giovanna Bianchi-Scarrà, Alberto Inga, Paola Ghiorzo
CDKN2A coding region germline variants are associated with pancreatic adenocarcinoma (PC) susceptibility. Recently, we described functional germline 5'UTR CDKN2A variants from melanoma patients affecting the post-transcriptional regulation of p16INK4a mRNA that is dependent, at least in part, on an Internal Ribosome Entry Site (IRES) in the 5'UTR region. Here we describe a 5'UTR c.-201_-198delinsCTTT CDKN2A variant (frequency 0.0028 based on 350 PC patients), which seems to be private to PC, since it has never been found in public databases nor in thousands of melanoma patients tested...
2017: PloS One
https://www.readbyqxmd.com/read/29216209/preliminary-study-of-tumor-heterogeneity-in-imaging-predicts-two-year-survival-in-pancreatic-cancer-patients
#18
Jayasree Chakraborty, Liana Langdon-Embry, Kristen M Cunanan, Joanna G Escalon, Peter J Allen, Maeve A Lowery, Eileen M O'Reilly, Mithat Gönen, Richard G Do, Amber L Simpson
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in the United States with a five-year survival rate of 7.2% for all stages. Although surgical resection is the only curative treatment, currently we are unable to differentiate between resectable patients with occult metastatic disease from those with potentially curable disease. Identification of patients with poor prognosis via early classification would help in initial management including the use of neoadjuvant chemotherapy or radiation, or in the choice of postoperative adjuvant therapy...
2017: PloS One
https://www.readbyqxmd.com/read/29215586/investigation-of-polyamine-metabolism-and-homeostasis-in-pancreatic-cancers
#19
Chelsea Massaro, Jenna Thomas, Otto Phanstiel Iv
Pancreatic cancers are currently the fourth leading cause of cancer-related death and new therapies are desperately needed. The most common pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC). This report describes the development of therapies, which effectively deplete PDAC cells of their required polyamine growth factors. Of all human tissues, the pancreas has the highest level of the native polyamine spermidine. To sustain their high growth rates, PDACs have altered polyamine metabolism, which is reflected in their high intracellular polyamine levels and their upregulated import of exogenous polyamines...
December 7, 2017: Medical Sciences: Open Access Journal
https://www.readbyqxmd.com/read/29213099/apparent-diffusion-coefficient-adc-predicts-therapy-response-in-pancreatic-ductal-adenocarcinoma
#20
M Trajkovic-Arsic, I Heid, K Steiger, A Gupta, A Fingerle, C Wörner, N Teichmann, S Sengkwawoh-Lueong, P Wenzel, A J Beer, I Esposito, R Braren, J T Siveke
Recent advances in molecular subtyping of Pancreatic Ductal Adenocarcinoma (PDAC) support individualization of therapeutic strategies in this most aggressive disease. With the emergence of various novel therapeutic strategies and neoadjuvant approaches in this quickly deteriorating disease, robust approaches for fast evaluation of therapy response are urgently needed. To this aim, we designed a preclinical imaging-guided therapy trial where genetically engineered mice harboring endogenous aggressive PDAC were treated with the MEK targeting drug refametinib, which induces rapid and profound tumor regression in this model system...
December 6, 2017: Scientific Reports
keyword
keyword
105689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"